Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults

Cytokine

Volumn 55, Issue 1, 2011, Pages 56-61

  Komorowski, Jan ^a   Jankiewicz Wika, Joanna ^a   Kolomecki, Krzysztof ^a   Cywinski, Jacek ^b   Piestrzeniewicz, Katarzyna ^a   Swietoslawski, Jacek ^a   Stepien, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b N Copernicus Hospital   (Poland)

Author keywords

Bariatric surgery; E selectin; Endostatin; Obesity; Osteopontin

Indexed keywords

C REACTIVE PROTEIN; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INSULIN; OSTEOPONTIN;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GASTRIC BANDING; GASTROPLASTY; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC CIRCULATION; TREATMENT RESPONSE; VERTICAL BANDING SURGERY; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; E-SELECTIN; ENDOSTATINS; FEMALE; GASTROPLASTY; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; OSTEOPONTIN; YOUNG ADULT;

EID: 79956358260     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.03.020     Document Type: Article

References (60)

1. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
2. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008, 118:2992-3002.
3. Suganami T., Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leuk Biol 2010, 88:1-7.
4. Shah R., Hinkle C.C., McGillicuddy F.C., Kim R., Hannenhalli S., Cappola T.P., et al. Gene profiling of human adipose tissue during evoked inflammation in vivo. Diabetes 2009, 58:2211-2219.
5. Boulouumie A., Casteilla L., Lafontan M. Adipose tissue lymphocytes, macrophages in obesity, insulin resistance. Markers or markers, and which comes first?. Arterioscler Thromb Vasc Biol 2008, 28:1211-1213.
6. Kintscher U., Hartge M., Hess K., Foryst-Ludwig A., Clemenz M., Wabitsch M., et al. Resistance. Arterioscler Thromb Vasc Biol 2008, 28:1304-1310.
7. Matter C.M., Stein M.A.S. A dual role of DC4+ T cells in adipose tissue?. Circ Res 2009, 104:928-930.
8. Connelly J.B., Duaso M.J., Butler G. A systematic review of controlled trials of interventions to prevent childhood obesity, overweight: a realistic synthesis of the evidence. Public Health 2007, 121:510-517.
9. Eckel R.H. Nonsurgical management of obesity in adults. N Engl J Med 2008, 358:1941-1950.
10. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., et al. Bariatric surgery: a systematic review and meta-analysis. J Am Med Assoc 2004, 292:1724-1737.
11. Buchwald H. Surgery on obese patients. J Am Coll Surg 2010, 210:166-177.
12. Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K, Swietoslawski J, Stepien H, et al. Impact of vertical banded gastroplasty on body weight, insulin resistance, adipocytokine, inflammation and metabolic syndrome markers in morbid obesity patients. Endocrinol Pol 2011;62(2): in press.
13. Thompson AM, Zhang Y, Tong W, Xu T, Chen J, Zhao L, et al. Association of obesity and biomarkers of inflammation and endothelial dysfunction in adults in Inner Mongolia, China. Int J Cardiol, 2010 [Epub ahead of print].
14. Glowinska-Olszewska B., Tolwinska J., Urban M. Interrelationship between endothelial dysfunction of the carotid arterie, adhesion molecules in obese hypertensive children, adolescents. Pediatr Endocrinol Diabetes Metab 2007, 13:7-14.
15. Rupnick M.A., Panigrahy D., Zhang Ch.-Y., Dallabrida S.M., Lowell B.B., Langer L.R., et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002, 99:10730-10735.
16. Silha J.V., Krsek M., Sucharda P., Murphy L.J. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 2005, 11:1308-1314.
17. Uede T., Katagiri Y., Iizuka J., Murakami M. Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein?. Microbiol Immunol 1997, 41:641-648.
18. Turner E.T., Harris A.L., Melmed S., Wass J.A.H. Angiogenesis in endocrine tumors. Endocr Rev 2003, 5:600-632.
19. Giachelli C.M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000, 19:615-622.
20. Johnson G.A., Burghardt R.C., Joyce M.M., Spencer T.E., Bazer F.W., Gray C.A., et al. Osteopontin is synthesized by uterine glands and a 45-kDa cleavage fragment is localized at the uterine-placental interface throughout ovine pregnancy. Biol Reprod 2003, 69:92-98.
21. O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003, 14:479-488.
22. Rittling S.R. Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881.
23. Ashkar S., Weber G.F., Panoutsakopulou V., Sanchirico M.E., Jansson M., Zawaideh S., et al. Eta-1 (osteopontin): an early component of type-1 (cell mediated) immunity. Sciences 2000, 287:860-864.
24. Oguchi Y., Kawakami K., Kon S., Segawa T., Maeda M., Uede T., et al. Penicillium marneffei causes osteopontin-mediated production of interleukin-12 by peripheral blood mononuclear cells. Infest Immun 2002, 70:1042-1048.
25. Jurczynska J., Zieleniewski W., Stepien H., Komorowski J. Angiogenic and anti-angiogenic factors in adrenal tumours. Endocrinol Pol 2006, 6:633-640.
26. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
27. Lim Y.C., Henault L., Wagers A.J., Kansas G.S., Luscinskas F.W., Lichtman A.H. Expression of functional selectin ligands on Th cells is differentially regulated by IL-12 and IL-4. J Immunol 1999, 162:3193-3201.
28. Kansas G.S. Selectins, their ligands: current concepts and controversies. Blood 1996, 88:3259-3287.
29. Tedder T.F., Steeber D.A., Chen A., Engel P. The selectins: vascular adhesion molecules. FASEB J 1995, 9:866-873.
30. Zanni M.V., Stanley T.L., Makimura H., Chen C.Y., Grinspoon S.K. Effects of TNF-alpha antagonism on E-selectin in obese subjects with metabolic dysregulation. Clin Endocrinol (Oxf) 2009, 73:48-54.
31. Pontiroli A.E., Frigè F., Paganelli M., Folli F. In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: effect of weight loss through surgery. Obes Surg 2009, 6:745-750.
32. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US Adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
33. Kintscher U., Hartge M., Hess K., Foryst-Ludwig A., Clemennz M., Wabitsch M., et al. Resistance. Arterioscler Thromb Vasc Biol 2008, 8:1304-1310.
34. Nishimura S., Manabe I., Nagasaki M., Seo K., Yamashita H., Hosoya Y., et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 2008, 118:710-721.
35. Riedl M., Vila G., Maier C., Handisurya A., Shakeri-Manesch S., Prager G., et al. Resistance. J Clin Endocrinol Metab 2008, 93:2307-2312.
36. Gomez-Ambrosi J., Catalan V., Ramirez B., Rodriguez A., Colina I., Silva C., et al. Plasma osteopontin levels and expression in adipose tissue are increase in obesity. J Clin Endocrinol Metab 2007, 92:3719-3727.
37. Bertola A., Deveaux V., Bonnafous S., Rousseau D., Anty R., Wakkach A., et al. Obesity. Diabetes 2009, 58:125-133.
38. Nomiyama T., Perez-Tilve D., Ogawa D., Gizard F., Zhao Y., Heywood E.B., et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007, 117:2877-2888.
39. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993, 92:1686-1696.
40. Giachelli C.M., Liaw L., Murry C.E., Schwartz S.M., Almeida M. Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 1995, 760:109-126.
41. O'Brien K.D., Kuusisto J., Reichenbach D.D., Ferguson M., Giachelli C., Alpers C.E., et al. Lesions. Circulation 1995, 92:2163-2218.
42. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
43. Giachelli C.M., Lombardi D., Johnson R.J., Murry C.E., Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 1998, 152:353-358.
44. Weber G.F., Zawaideh S., Hikita S., Kumar V.A., Cantor H., Ashkar S. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukoc. Biol. 2002, 72:752-761.
45. O'Regan A.W., Nau G.J., Chupp G.L., Berman J.S. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000, 21:475-478.
46. O'Regan A.W., Chupp G.L., Lowry J.A., Goetschkes M., Mulligan N., Berman J.S. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999, 162:1024-1031.
47. Schaller G., Aso Y., Schernthaner G.H., Kopp H.P., Inukai T., Kriwanek S., et al. Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg 2009, 19:351-356.
48. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
49. Nishimura S., Manabe I., Nagasaki M., Hosoya Y., Yamashita H., Fujita H., et al. Stromal cells and blood vessels. Diabetes 2007, 56:1517-1526.
50. Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170:191-203.
51. Alvarado R., de Seijo G., Hernandez B., Jordan P. Effect of high glucose load on serum adhesion markers in obese women. Med Clin (Barc) 2009, 132:407-413.
52. Hanusch-Enserer U., Zorn G., Wojta J., Kopp C.W., Prager R., Koenig W., et al. Non-conventional markers of atheroclerosis before and after gastric banding surgery. Eur Heart J 2009, 12:1516-1526.
53. Thompson AM, Zhang Y, Tong W, Xu T, Chen J, Zhao L, et al. Association of obesity and biomarkers of inflammation and endothelial dysfunction in adults in Inner Mongolia, China. Int J Cardiol, 2010 [Epub ahead of print].
54. Folkman J. Angiogenesis, an organizing principle for drug discovery?. Nat Rev 2007, 6:273-285.
55. Ren B., Höti N., Rabasseda X., Wang Y.Z., Wu M. The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003, 25:215-224.
56. Bono P., Teerenhovi L., Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin, lymphoma. Cancer 2003, 7:2767-2775.
57. Feldman A.L., Tamarkin L., Paciotti G.F., Simpson B.W., Linehan W.M., Yang C.J., et al. Cancer. Clin Cancer Res 2000, 6:4628-4634.
58. Feldman A.L., Pak H., Yang J.C., Alexander H.R., Libutti S.K. Serum endostatin levels are elevated in patients with soft tissue, sarcoma. Cancer 2001, 91:1525-1529.
59. Silha J.V., Ksek M., Sucharda P., Murphy L.J. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 2005, 11:1308-1314.
60. Brixius K., Schoenberger S., Ladage D., Knigge H., Falkowski G., Hellmich M., et al. Long-term endurance exercise decreases antiangiogenic endostatin signaling in overweight men aged 50-60 years. Br J Sports Med 2008, 432:126-129.